Back to Search
JAE HONG KIM M.D.
M.D.
Neonatal-Perinatal Medicine Physician
NPI: 1639242977Individual
Specialties, Licenses & Credentials
Pediatrics Physician
Pediatrics
Code: 208000000X
C52431(CA)
Neonatal-Perinatal Medicine PhysicianPrimary
Pediatrics — Neonatal-Perinatal Medicine
Code: 2080N0001X
C52431(CA)35.136969(OH)
Pediatric Gastroenterology Physician
Pediatrics — Pediatric Gastroenterology
Code: 2080P0206X
C52431(CA)
Clinical Trials (1)
1
Linked Trials
0
Recruiting
0
With Results
Research & Publications (20)
Psoriasis harbors multiple pathogenic type 17 T-cell subsets: Selective modulation by risankizumab.
PMID 39978685·J Allergy Clin Immunol·2025
8-other
Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment.
PMID 28927890·J Invest Dermatol·2018
3-trial
Proportion of CD4CD49bLAG-3Type 1 Regulatory T Cells in the Blood of Psoriasis Patients Inversely Correlates with Psoriasis Area and Severity Index.
PMID 29890167·J Invest Dermatol·2018
8-other
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
PMID 30097359·Lancet·2018
3-trial
Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis.
PMID 27686018·Annu Rev Med·2017
6-review
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
PMID 28423301·N Engl J Med·2017
3-trial
The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes.
PMID 27185339·J Invest Dermatol·2016
4-observational
Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets.
PMID 26763436·J Invest Dermatol·2016
4-observational
Patients With Psoriasis and Personalized Trade-offs in Treatment Decisions-Lessons Learned From Focus Groups.
PMID 27028481·JAMA Dermatol·2016
8-other
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.
PMID 25769911·J Allergy Clin Immunol·2015
2-rct
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris.
PMID 14707118·J Exp Med·2004
4-observational
An algorithm for the accurate identification of benign liver lesions.
PMID 14769319·Am J Surg·2004
8-other
Ocular surface reconstruction: limbal stem cell transplantation.
PMID 12683249·Ophthalmol Clin North Am·2003
6-review
Increased biliary fistulas after liver resection with the harmonic scalpel.
PMID 14509335·Am Surg·2003
4-observational
Preliminary report on the safety of heparin for deep venous thrombosis prophylaxis after severe head injury.
PMID 12131387·J Trauma·2002
8-other
Microsurgical anatomic features and nomenclature of the paraclinoid region.
PMID 10719864·Neurosurgery·2000
8-other
Race and ethnicity correlate with survival in patients with gastric adenocarcinoma.
PMID 19622590·Ann Oncol·2010
8-other
Trifurcate feed-forward regulation of age-dependent cell death involving miR164 in Arabidopsis.
PMID 19229035·Science·2009
8-other
FcRn in the yolk sac endoderm of mouse is required for IgG transport to fetus.
PMID 19234152·J Immunol·2009
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 3333 BURNET AVENUE, ML 7009
CINCINNATI, OH 45229 - Phone
- (513) 636-4830
Quick Facts
- NPI
- 1639242977
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 4
- Locations
- 2
- Clinical Trials
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile